Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th

Phio Pharmaceuticals will present positive clinical data on March 28th regarding its Phase 1b study of INTASYL PH-762, which focuses on treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The study evaluated the safety and tolerability of the neoadjuvant use of intratumoral PH-762. The presentation is expected to provide insights into the potential of this treatment for specific carcinomas.